膀胱癌中的FGFR改变:从分子发病机制到精准肿瘤学
该综述聚焦尿路上皮癌中FGFR通路改变(尤以FGFR3最常见)的生物学、分子诊断与临床应用。文章指出FGFR2/3改变是非肌层浸润性、肌层浸润性、转移性及上尿路尿路上皮癌中可操作的生物标志物,并汇总了综合基因组分析、组织测序、血浆循环肿瘤DNA、尿液分子检测及分子残留病灶评估在诊断、治疗选择、监测中的拓展作用,同时提及联合策略、下一代FGFR抑制剂及早期使用FGFR靶向治疗的最新临床研究支持。
要点
- FGFR2/3改变是各分期尿路上皮癌中可操作的生物标志物。
- 液体活检与尿液分子检测拓展了FGFR标志物在监测中的应用。
- 联合策略与下一代FGFR抑制剂是当前研究支持的方向。
核心结论
- FGFR改变已成为尿路上皮癌分子分型与精准管理的重要组成部分。
- 分子诊断、液体活检、生物标志物指导治疗与下一代FGFR抑制剂的持续进展预期将进一步实现个体化诊疗。
研究设计与样本
- 本文为综述,汇总尿路上皮癌中FGFR改变的生物学、分子诊断与不断演变的临床应用。
主要发现
- FGFR3改变是尿路上皮癌中最常见的基因组事件之一,部分FGFR2融合也可识别可能从靶向治疗获益的患者。
- 综合基因组分析、组织测序、血浆循环肿瘤DNA、尿液分子检测及分子残留病灶评估在诊断、治疗选择、监测与疾病监控中的作用正在拓展。
- 近期临床研究支持联合策略、下一代FGFR抑制剂及更早使用FGFR靶向治疗。
- 人工智能辅助病理与整合多组学标志物等新兴技术可能进一步改善患者选择。
临床怎么用
- 将FGFR生物标志物整合入当代尿路上皮癌管理框架,用于治疗选择与疾病监测。
- 关注联合策略、下一代FGFR抑制剂及早期使用FGFR靶向治疗的研究进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Alterations in the fibroblast growth factor receptor (FGFR) pathway, particularly FGFR3, are among the most common genomic events in urothelial carcinoma (UC) and represent a cornerstone of precision oncology. Although FGFR3 alterations predominate, selected FGFR2 fusions also identify patients who may benefit from targeted therapy. This review summarizes the biology, molecular diagnostics, and evolving clinical applications of FGFR alterations in UC. OBSERVATIONS: FGFR2/3 alterations are clinically actionable biomarkers across non-muscle-invasive, muscle-invasive, metastatic, and upper-tract UC. Comprehensive genomic profiling, tissue sequencing, plasma circulating tumor DNA, urine-based molecular assays, and molecular residual disease assessment are expanding their roles in diagnosis, treatment selection, surveillance, and disease monitoring. Recent clinical studies support combination strategies, next-generation FGFR inhibitors, and earlier use of FGFR-directed therapy, while emerging technologies, including artificial intelligence-assisted pathology and integrated multi-omic biomarkers, may further improve patient selection. CONCLUSIONS AND RELEVANCE: FGFR alterations have become integral to the molecular classification and precision management of UC. Continued advances in molecular diagnostics, liquid biopsy, biomarker-guided therapy, and next-generation FGFR inhibitors are expected to further personalize care. This review provides a practical framework for integrating FGFR biomarkers into contemporary management and highlights emerging developments likely to influence future clinical practice.
引用
- Collins K, Cheng L. FGFR Alterations in Bladder Cancer-From Molecular Pathogenesis to Precision Oncology. JAMA Oncol. 2026. PMID: 42955008. doi:10.1001/jamaoncol.2026.4196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。